Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Cleveland BioLabs: Potential Funding Could Be Pivotal Event

By Edison Stock MarketsJan 16, 2013 01:11AM ET
www.investing.com/analysis/cleveland-biolabs:-potential-funding-could-be-pivotal-event-151055
Cleveland BioLabs: Potential Funding Could Be Pivotal Event
By Edison   |  Jan 16, 2013 01:11AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
Investment summary: First line of (bio)defence
Cleveland BioLabs’ (CBLI) biodefence franchise is fundamental to its near-term investment case and 2013 should see significant progress in the development of Entolimod (CBLB502) as the first available treatment for acute radiation syndrome (ARS). A potential development funding contract from BARDA in H113 is a major stock catalyst and financing event. Pivotal studies in animals and humans are planned for 2013 and a BLA submission is targeted for Q414. Entolimod, a TLR5 agonist, also holds potential as an anti-cancer agent, with a Phase I study to complete in Q413.

Animal efficacy rules OK
The FDA created the Animal Efficacy Rule in 2002 to encourage and enable the development of new products when human efficacy studies are not ethical or feasible. To date, four products have been approved under this pathway, two gaining approval in 2012 (raxibacumab for inhalational anthrax and levofloxacin for plague), confirming the viability of this regulatory process for Entolimod.

Efficacy in animals, safety in humans
A pivotal study of Entolimod in 179 non-human primates (single im admin 25 hours after total body irradiation) demonstrated efficacy at the highest-anticipated radiation level requested by the FDA (60-day survival rate of 75% for Entolimod vs 28% placebo), a dose response and validation of biomarkers (G-CSF and IL-6). Human safety trials have been completed in 150 healthy volunteers and Cleveland is planning further pivotal animal efficacy and human safety studies through 2013. A pre-emergency use authorisation (EUA) submission is also targeted for Q313; most countermeasures stockpiled by the US government are procured through an EUA.

Longer-term oncology play
Entolimod’s TLR5 agonist activity delivers protective qualities (via healing cytokines/ anti-apoptotic factors) but also mobilises an innate immune response, particularly against TLR5+ tumours (eg liver, breast, colon, lung). Cleveland is conducting a Phase I study of Entolimod in 48-patients with unresectable solid tumours, with results due in H114. Two further oncology candidates (CBL0137 and CBL0102) are also undergoing Phase I studies through a Russian subsidiary, Incuron.

Valuation: Undemanding $35m EV
With $35m cash after a $13.8m public offering in October 2012, Cleveland’s EV of $35m is undemanding with potential upside from a BARDA contract in H113. The stock may also offer an attractive entry point with a view to Cleveland’s future in oncology. We intend to initiate full coverage of Cleveland BioLabs in due course.

To Read the Entire Report Please Click on the pdf File Below.
Cleveland BioLabs: Potential Funding Could Be Pivotal Event
 

Related Articles

Cleveland BioLabs: Potential Funding Could Be Pivotal Event

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email